Clinical trial milestones for its lead iNKT therapy agenT-797 include Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. Key clinical highlights include durable responses with agenT-797 in checkpoint- and chemotherapy-refractory solid tumors, including complete remissions >2 years and multi-year survivors, with no ≥Grade 3 CRS or neurotoxicity reported.
Cyborg Score Rationale
The company demonstrates promising clinical data with durable responses and safety profile in difficult-to-treat cancers. However, cash runway through 2026 presents near-term financing risk, and the company remains in early-stage clinical development.
Top Insights
Recent translational data shows significant iNKT cell depletion in lung-associated lymph nodes from advanced IPF patients, supporting mechanistic rationale for iNKT replenishment strategies in fibrotic lung disease.
MiNK-215, an IL-15-enhanced FAP-targeting CAR-iNKT program, showed preclinical data dismantling stromal barriers and enabling deep tumor-specific T cell infiltration in refractory lung and colorectal cancers.
Analyst consensus rates INKT as "Buy" with 12-month price target of $35.0, representing 215.88% upside.
The company launched an NIH- and philanthropically funded GvHD collaboration with UW–Madison and plans a Phase 2+ severe pulmonary disease trial using FDA-validated endpoints.
Named Competitors
CAR-T Cell Therapy — Chimeric antigen receptor T cell therapies for oncology
CAR-T Cell Therapy — Off-the-shelf and personalized cell therapy programs
Checkpoint Inhibitors — Keytruda and combination immunotherapy approaches
Recent Developments
(Feb 2026) Presented translational human lung data at Keystone Symposia showing significant depletion of iNKT cells in lung-associated lymph nodes from end-stage IPF patients.
(Nov 2025) Published preclinical data for MiNK-215, an allogeneic, IL-15-enhanced FAP-targeting CAR-iNKT designed to remove FAP+ cancer-associated fibroblasts and boost immune infiltration in solid tumors.
(Nov 2025) Reported Q3 2025 results with durable responses for agenT-797 in checkpoint- and chemotherapy-refractory solid tumors, including complete remissions >2 years.
Open the full interactive MiNK Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.